145 related articles for article (PubMed ID: 14977451)
1. Improvement of HDL- and LDL-cholesterol levels in diabetic subjects by feeding bread containing chitosan.
Ausar SF; Morcillo M; León AE; Ribotta PD; Masih R; Vilaro Mainero M; Amigone JL; Rubin G; Lescano C; Castagna LF; Beltramo DM; Diaz G; Bianco ID
J Med Food; 2003; 6(4):397-9. PubMed ID: 14977451
[TBL] [Abstract][Full Text] [Related]
2. The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes.
Erdman DM; Cook CB; Greenlund KJ; Giles WH; El-Kebbi I; Ryan GJ; Gallina DL; Ziemer DC; Dunbar VG; Phillips LS
Diabetes Care; 2002 Jan; 25(1):9-15. PubMed ID: 11772894
[TBL] [Abstract][Full Text] [Related]
3. Ethnicity and glycaemic control are major determinants of diabetic dyslipidaemia in Malaysia.
Ismail IS; Nazaimoon W; Mohamad W; Letchuman R; Singaraveloo M; Hew FL; Shuguna C; Khalid BA
Diabet Med; 2001 Jun; 18(6):501-8. PubMed ID: 11472471
[TBL] [Abstract][Full Text] [Related]
4. The pattern of dyslipidemia among urban African-Americans with type 2 diabetes.
Cook CB; Erdman DM; Ryan GJ; Greenlund KJ; Giles WH; Gallina DL; El-Kebbi IM; Ziemer DC; Ernst KL; Dunbar VG; Phillips LS
Diabetes Care; 2000 Mar; 23(3):319-24. PubMed ID: 10868858
[TBL] [Abstract][Full Text] [Related]
5. Intensive lipid-lowering strategy in patients with diabetes mellitus.
Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
[TBL] [Abstract][Full Text] [Related]
6. The long-term effects of rosiglitazone on serum lipid concentrations and body weight.
Shim WS; Do MY; Kim SK; Kim HJ; Hur KY; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
Clin Endocrinol (Oxf); 2006 Oct; 65(4):453-9. PubMed ID: 16984237
[TBL] [Abstract][Full Text] [Related]
7. Serum lipids and glucose control: the SEARCH for Diabetes in Youth study.
Petitti DB; Imperatore G; Palla SL; Daniels SR; Dolan LM; Kershnar AK; Marcovina S; Pettitt DJ; Pihoker C;
Arch Pediatr Adolesc Med; 2007 Feb; 161(2):159-65. PubMed ID: 17283301
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients.
Ahmad Khan H
Acta Diabetol; 2007 Dec; 44(4):193-200. PubMed ID: 17786383
[TBL] [Abstract][Full Text] [Related]
10. Effect of diabetes on uremic dyslipidemia.
Kimoto E; Shoji T; Emoto M; Miki T; Tabata T; Okuno Y; Ishimura E; Inaba M; Nishizawa Y
J Atheroscler Thromb; 2002; 9(6):305-13. PubMed ID: 12560592
[TBL] [Abstract][Full Text] [Related]
11. Decrease in serum LDL cholesterol with microcrystalline chitosan.
Wuolijoki E; Hirvelä T; Ylitalo P
Methods Find Exp Clin Pharmacol; 1999 Jun; 21(5):357-61. PubMed ID: 10420392
[TBL] [Abstract][Full Text] [Related]
12. Decreased peripheral blood mitochondrial DNA content is related to HbA1c, fasting plasma glucose level and age of onset in type 2 diabetes mellitus.
Xu FX; Zhou X; Shen F; Pang R; Liu SM
Diabet Med; 2012 Jul; 29(7):e47-54. PubMed ID: 22211946
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a homogeneous assay with a precipitation method for the measurement of HDL cholesterol in diabetic patients.
Jensen T; Truong Q; Frandsen M; Dinesen B; Stender S
Diabetes Care; 2002 Nov; 25(11):1914-8. PubMed ID: 12401732
[TBL] [Abstract][Full Text] [Related]
14. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia.
Reyna-Villasmil N; Bermúdez-Pirela V; Mengual-Moreno E; Arias N; Cano-Ponce C; Leal-Gonzalez E; Souki A; Inglett GE; Israili ZH; Hernández-Hernández R; Valasco M; Arraiz N
Am J Ther; 2007; 14(2):203-12. PubMed ID: 17414591
[TBL] [Abstract][Full Text] [Related]
15. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients.
Taniguchi A; Nakai Y; Sakai M; Yoshii S; Hamanaka D; Hatae Y; Kawata M; Yamanouchi K; Okumura T; Doi K; Tokuyama K; Nagasaka S; Fukushima M
Metabolism; 2002 May; 51(5):544-8. PubMed ID: 11979383
[TBL] [Abstract][Full Text] [Related]
16. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group
Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
[TBL] [Abstract][Full Text] [Related]
17. Oat bran and cholesterol reduction: evidence against specific effect.
Bremer JM; Scott RS; Lintott CJ
Aust N Z J Med; 1991 Aug; 21(4):422-6. PubMed ID: 1659358
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Tikkanen MJ; Laakso M; Ilmonen M; Helve E; Kaarsalo E; Kilkki E; Saltevo J
Diabetes Care; 1998 Apr; 21(4):477-81. PubMed ID: 9571327
[TBL] [Abstract][Full Text] [Related]
20. Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients.
Ybarra J; James RW; Makoundou V; Bioletto S; Golay A
Diabetes Metab; 2001 Dec; 27(6):701-8. PubMed ID: 11852380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
